Objective: To systematically evaluate the clinical efficacy of anti-anxiety drugs in the treatment of sudden deafness (SD) with anxiety. Methods: PubMed, PMC, Embase, CNKD and VIP were searched for randomized controlled trials (RCTS) on the use of anti-anxiety drugs as adjunctive interventions in the treatment of sudden deafness with anxiety. Then, according to the specific research content, the appropriate literature was selected for inclusion and analysis. Cochrane risk bias assessment tool was used to evaluate the quality of the included studies. After determining the quality of the literature, RevMan5.4.1 software was used to conduct a meta-analysis of the Self-Rating Anxiety Scale (SAS) score, cure rate and effective rate in the literature. Results: A total of 235 articles were retrieved, and 15 articles were included in the analysis of the effect of anti-anxiety drugs in the adjuvant treatment of SD patients with anxiety. A total of 1190 patients in the experimental group and 1089 patients in the control group were included in this study. The results of Meta-analysis showed that the use of anxiolytic drugs in the adjuvant treatment of SD patients with anxiety could significantly reduce SAS scores [95%CI (-17.96, -8.72), P<0.00001], significantly improved the cured rate [95%CI (9.00, 14.61), P<0.00001], and the overall effective rate was significantly higher than the conventional treatment [95%CI (17.51, 29.09), P<0.00001]. Conclusion: Compared with the conventional treatment group, anti-anxiety drugs can improve the anxiety of SD patients and improve the overall effective rate of hearing. Therefore, anti-anxiety drugs have a significant effect on the auxiliary treatment of SD patients with anxiety.